For research use only, not for therapeutic use.
OSS_128167（Cat No.:I012947）is a novel small molecule that functions as an inhibitor of specific signaling pathways implicated in cancer progression and metastasis. This compound has shown promise in preclinical studies for its ability to target tumor cell proliferation and enhance apoptosis. By interfering with key molecular targets, OSS_128167 aims to disrupt the microenvironment that supports tumor growth. Research is ongoing to assess its efficacy across various cancer models, as well as its potential role in combination therapies. Its unique mechanism of action positions OSS_128167 as a candidate for further clinical development in oncology.
| Catalog Number | I012947 |
| CAS Number | 887686-02-4 |
| Molecular Formula | C₁₉H₁₄N₂O₆ |
| Purity | ≥95% |
| Target | Sirtuin |
| Solubility | DMSO: 103.3 mg/mL |
| Storage | 2-8°C |
| IUPAC Name | 5-[[3-(furan-2-carbonylamino)benzoyl]amino]-2-hydroxybenzoic acid |
| InChI | InChI=1S/C19H14N2O6/c22-15-7-6-13(10-14(15)19(25)26)20-17(23)11-3-1-4-12(9-11)21-18(24)16-5-2-8-27-16/h1-10,22H,(H,20,23)(H,21,24)(H,25,26) |
| InChIKey | HTJWLEGCECXGSQ-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC(=C1)NC(=O)C2=CC=CO2)C(=O)NC3=CC(=C(C=C3)O)C(=O)O |
| Reference | [1]. Parenti MD, et al. Discovery of novel and selective SIRT6 inhibitors. J Med Chem. 2014 Jun 12;57(11):4796-804.<br>[2]. Cea M, et al. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 3;127(9):1138-50. |
